Pre-publication history
Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer
-
* Corresponding author: Hee J Chang heejincmd@yahoo.com
- † Equal contributors
BMC Cancer 2009, 9:246 doi:10.1186/1471-2407-9-246
Pre-publication versions of this article and reviewers' reports
| Original Submission - Version 1 | Manuscript | 17 Mar 2009 | |
| Reviewer's Report | Stefan Kubicka | 17 Apr 2009 | |
| Reviewer's Report | Dirk Jaeger | 19 Apr 2009 | |
| Reviewer's Report | Carsten Nieder | 14 May 2009 | |
| Resubmission - Version 2 | Manuscript | Author's comment | 29 Jun 2009 |
| Reviewer's Report | Carsten Nieder | 08 Jul 2009 | |
| Resubmission - Version 3 | Manuscript | 12 Jul 2009 | |
| Editorial acceptance | 13 Jul 2009 | ||
| Published | 21 Jul 2009 |